联合药物治疗在变应性鼻炎治疗中的应用:系统评价与荟萃分析
该系统评价与荟萃分析纳入53项随机对照试验,比较7种联合用药方案与单药治疗变应性鼻炎的效果。结果显示,抗组胺药单药未控制症状时加用减充血剂、盐水或白三烯受体拮抗剂可改善结局;鼻内糖皮质激素单药无效时加用鼻内抗组胺药可改善鼻部症状,加用白三烯受体拮抗剂可改善眼部症状,盐水冲洗可改善生活质量。
要点
- 抗组胺药单药未控制症状时,加用减充血剂、盐水或白三烯受体拮抗剂可改善结局。
- 鼻内糖皮质激素单药无效时,加用鼻内抗组胺药可改善鼻部症状。
- 鼻内糖皮质激素单药无效时,加用白三烯受体拮抗剂可改善眼部症状,盐水冲洗可改善生活质量。
核心结论
- 抗组胺药单药治疗未能控制症状后,加用减充血剂、盐水或白三烯受体拮抗剂可改善结局。
- 鼻内糖皮质激素单药治疗无效时,加用鼻内抗组胺药可改善鼻部症状,加用白三烯受体拮抗剂可改善眼部症状,盐水冲洗可改善生活质量。
研究设计与样本
- 系统检索PubMed和EMBASE,检索更新至2021年11月4日。
- 纳入比较联合治疗与单药治疗效果的随机对照试验。
- 共纳入53项研究,涉及7种比较:抗组胺药-减充血剂 vs 抗组胺药;抗组胺药-白三烯受体拮抗剂 vs 抗组胺药;鼻内糖皮质激素-抗组胺药 vs 鼻内糖皮质激素;鼻内糖皮质激素-白三烯受体拮抗剂 vs 鼻内糖皮质激素;鼻内糖皮质激素-减充血剂 vs 鼻内糖皮质激素;鼻内糖皮质激素-盐水冲洗 vs 鼻内糖皮质激素;抗组胺药-盐水冲洗 vs 抗组胺药。
- 结局指标为复合鼻部症状评分、复合眼部症状评分、生活质量和不良事件。
主要发现
- 与单用抗组胺药相比,抗组胺药-减充血剂联合改善复合鼻部症状。
- 与单用抗组胺药相比,抗组胺药-白三烯受体拮抗剂联合改善常年性变应性鼻炎患者的鼻部症状。
- 与单用抗组胺药相比,抗组胺药-鼻用盐水联合改善症状和生活质量。
- 与单用鼻内糖皮质激素相比,鼻内糖皮质激素-鼻内抗组胺药联合改善鼻部症状、眼部症状和生活质量。
- 与单用鼻内糖皮质激素相比,鼻内糖皮质激素-白三烯受体拮抗剂联合改善眼部症状但不改善鼻部症状,鼻内糖皮质激素-鼻用盐水联合改善生活质量但不改善症状。
临床怎么用
- 抗组胺药单药治疗未能控制症状后,加用减充血剂、盐水或白三烯受体拮抗剂可改善结局。
- 鼻内糖皮质激素单药治疗无效时,加用鼻内抗组胺药可改善鼻部症状,加用白三烯受体拮抗剂可改善眼部症状,盐水冲洗可改善生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antihistamines (ATH) and intranasal corticosteroids (INCS) are primary treatments for patients with allergic rhinitis (AR). When monotherapy of either primary treatment fails to control symptoms, combined medical therapy is an option. In this meta-analysis we assessed the additional effects of different medical combinations compared with primary treatments. METHODS: Systematic searches on PubMed and EMBASE were updated on November 4, 2021. Randomized, controlled trials comparing the effects of combinations with monotherapy were included. There were 7 comparisons: (1) ATH-decongestant vs ATH; (2) ATH-leukotriene receptor antagonist (LTRA) vs ATH; (3) INCS-ATH vs INCS; (4) INCS-LTRA vs INCS; (5) INCS-decongestion vs INCS; (6) INCS-saline irrigation vs INCS; and (7) ATH-saline irrigation vs ATH. Data were pooled for meta-analysis. Outcomes were composite nasal symptom score, composite ocular symptom score, quality of life (QoL), and adverse events. RESULTS: Fifty-three studies were included. Compared with ATH alone, the ATH-decongestant combination improved composite nasal symptoms; ATH-LTRA improved nasal symptoms in patients with perennial AR; and ATH-nasal saline improved both symptoms and QoL. Compared with INCS alone, the INCS-intranasal ATH combination improved nasal symptoms, ocular symptoms, and QoL; INCS-LTRA improved ocular symptoms but not nasal symptoms; and INCS-nasal saline improved QoL but not symptoms. There were no additional effects observed from adding oral ATH or topical decongestant to INCS. CONCLUSION: After ATH monotherapy fails to control symptoms, addition of decongestant, saline, or LTRA can improve the outcomes. When INCS monotherapy is ineffective, addition of intranasal ATH can improve nasal symptoms; LTRA can improve ocular symptoms, and saline irrigation can improve QoL.
引用
- Chitsuthipakorn W, Hoang MP, Kanjanawasee D, et al. Combined medical therapy in the treatment of allergic rhinitis: Systematic review and meta-analyses. Int Forum Allergy Rhinol. 2022. PMID: 35446512. doi:10.1002/alr.23015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。